PYXS Quote, Financials, Valuation and Earnings

Processa Pharmaceuticals, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of --. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Processa Pharmaceuticals, Inc.'s return on equity of -309.65%.

Pyxis Oncology, Inc. has a consensus price target of $6.93, signalling upside risk potential of 387.68%. On the other hand Processa Pharmaceuticals, Inc. has an analysts' consensus of $1.00 which suggests that it could grow by 1090.48%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Pyxis Oncology, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Pyxis Oncology, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Processa Pharmaceuticals, Inc. has a beta of 1.140, suggesting its more volatile than the S&P 500 by 13.98%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Processa Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Processa Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Processa Pharmaceuticals, Inc. quarterly revenues of --. Pyxis Oncology, Inc.'s net income of -$22M is lower than Processa Pharmaceuticals, Inc.'s net income of -$3.4M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Processa Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 30.86x versus -- for Processa Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of -242.19%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Spero Therapeutics, Inc.'s return on equity of -107.04%.

Pyxis Oncology, Inc. has a consensus price target of $6.93, signalling upside risk potential of 387.68%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 73.91%. Given that Pyxis Oncology, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Spero Therapeutics, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.448, suggesting its more volatile than the S&P 500 by 44.796%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 30.86x versus 4.36x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alpha Teknova, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of -41%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Alpha Teknova, Inc.'s return on equity of -22.95%.

Pyxis Oncology, Inc. has a consensus price target of $6.93, signalling upside risk potential of 387.68%. On the other hand Alpha Teknova, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 336.89%. Given that Pyxis Oncology, Inc. has higher upside potential than Alpha Teknova, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Alpha Teknova, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alpha Teknova, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alpha Teknova, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Alpha Teknova, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Alpha Teknova, Inc. quarterly revenues of $10.5M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Alpha Teknova, Inc.'s net income of -$4.3M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Alpha Teknova, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 30.86x versus 2.77x for Alpha Teknova, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 3.93%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Pyxis Oncology, Inc. has a consensus price target of $6.93, signalling upside risk potential of 387.68%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 158.58%. Given that Pyxis Oncology, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Xtant Medical Holdings, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.041, suggesting its less volatile than the S&P 500 by 104.125%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 56.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 30.86x versus 0.63x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.